Lenalidomid Sun (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4CRBN E3 ubiquitin ligase complex. This binding changes the complex’s substrate specificity, leading to degradation of transcription factors that regulate cell survival and immune function. The result is anti‑angiogenic activity, enhanced immune response, and direct inhibition of malignant cell growth.

The dosage of Lenalidomid Sun is individualized. The prescribing clinician determines the appropriate dose, schedule, and treatment duration based on the patient’s specific diagnosis, disease stage, renal function, and overall health status. Patients should follow the prescriber’s instructions exactly.

Lenalidomid Sun is contraindicated in pregnancy because it is teratogenic and can cause fetal harm. Women of child‑bearing potential must use effective contraception during treatment and for a defined period after the last dose. Breastfeeding is not recommended while taking lenalidomide.

To request Lenalidomid Sun, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Lenalidomid Sun belongs to the immunomodulatory drug class, offering a distinct mechanism compared with proteasome inhibitors or monoclonal antibodies. It provides oral administration, immunomodulatory and anti‑angiogenic effects, and is often used in combination regimens. Choice of therapy depends on disease characteristics, prior treatments, and patient tolerance.

Lenalidomid Sun should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and store it out of reach of children. Do not refrigerate or freeze unless otherwise directed by the supplier.

Lenalidomid Sun is taken orally, usually with water. The exact dosing schedule—such as daily or on specific days of a treatment cycle—is set by the prescriber. Patients should swallow the tablet whole and not crush or split it unless instructed.

Serious risks include thromboembolic events (blood clots), severe neutropenia (low white‑blood‑cell count), hepatotoxicity (liver injury), secondary malignancies, and severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for these complications and report any concerning symptoms promptly.

Lenalidomid Sun should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with uncontrolled infections or severe renal impairment without appropriate dose adjustment. Contraindications and precautions are assessed by the prescribing clinician.